Articles tagged "CD20"

2021 American Transplant Congress
Impact of Rituximab Induction Therapy on Donor-specific Anti-HLA Antibodies in Abo-compatible Kidney Transplant Recipients
T. Yagisawa¹, T. Kanzawa¹, K. Unagami², M. Furusawa¹, M. Inui¹, H. Ishida², K. Tanabe¹
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Development of de novo donor-specific anti-HLA antibodies (dnDSA) after kidney transplantation remains strongly associated with antibody-mediated rejection (AMR), which leads to poor graft outcome.…
2021 American Transplant Congress
Dissecting the Intrarenal Immune Response to Viral Infected Cells in Pediatric BK Virus-associated Nephropathy (BKVAN)
D. M. Okamura¹, S. W. Jackson¹, V. R. Dharnidharka², J. M. Smith¹
¹Pediatric Nephrology, Seattle Children's Hospital & Research Institute, Seattle, WA, ²Pediatric Nephrology, 2St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO
*Purpose: BKVAN is not only a cause of acute renal allograft injury but is a recognized cause of chronic allograft disease and in some patients,…
2020 American Transplant Congress
B Cell Depletion with Anti-CD20 mAb Exacerbates Anti-Donor CD4⁺T Cell Responses in Highly Sensitized Transplant Model
A. Tanaka, K. Ide, Y. Tanaka, M. Ohira, H. Tahara, H. Morimoto, H. Ohdan
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen antibodies (DSAs) have been associated with detrimental effects in transplant recipients. To eliminate preformed DSAs, we desensitized DSA-positive recipients…
2020 American Transplant Congress
T and B Lymphocyte Dynamics after Genetically-Modified Pig-To-Baboon Kidney Xenotransplantation with an Anti-CD40mAb-Based Immunosuppressive Regimen
A. Jagdale¹, H. Iwase¹, H. Nguyen¹, T. Yamamoto¹, D. Ayares², D. Anderson¹, D. Eckhoff¹, D. Cooper¹, H. Hara¹
¹Surgery, University of Alabama at birmingham, Birmingham, AL, ²Revivicor, Blacksburg, VA, VA
*Purpose: We have evaluated recovery of T and B lymphocytes and their subsets after depletion by anti-thymocyte globulin (ATG) and an anti-CD20mAb (Rituximab), followed by…
2020 American Transplant Congress
Rapid Preparation to Undergo ABO-Incompatible Living Donor Liver Transplantation for Acute Liver Failure
H. Hung¹, C. Lee², Y. Wang¹, J. Lee², C. Cheng¹, T. Wu¹, T. Wu¹, H. Chou¹, K. Chan¹, W. Lee²
¹Chang-gung Hospital, Taoyuan, Taiwan, ²Chang-gung Hospital, Taiyuan, Taiwan
*Purpose: Acute liver failure is a life-threatening condition and urgent liver transplantation is needed to save lives. In the circumstance of deceased and ABO-compatible (ABO-C)…
2020 American Transplant Congress
Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
Y. Kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Regulation, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Owing to limited organ availability, ABO-incompatible living kidney transplantation (ABO-ILKT) has been used extensively. Various forms of preconditioning therapies have been used alone or…
2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
I. Revuelta¹, E. De Sousa-Amorim¹, M. Lozano², D. Cucchiari¹, J. Cid², L. Peri³, E. Palou⁴, M. Musquera³, J. Martorell⁵, J. M. Campistol¹, F. Oppenheimer¹, F. Diekmann¹
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain, ²Apheresis and Cellular Therapy Unit, Hospital Clinic, Barcelona, Spain, ³Department of Urology, Hospital Clinic, Barcelona, Spain, ⁴Histocompatibility Lab. Department of Immunology, Hospital Clinic, Barcelona, Spain, ⁵Histocompatibility Lab, Department of Immunology, Hospital Clinic, Barcelona, Spain
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…
2019 American Transplant Congress
Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.
D. J. Sindi¹, A. Al Jedai², H. Aleid³, J. Brockmann⁴, M. Al-Awwami⁵, D. Alissa², E. De Vol⁶, H. Al Khabbaz⁷, L. Fajji⁸
¹Clinical Pharmacy, King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia, ²Clinical Pharmacy, KFSH&RC, Riyadh, Saudi Arabia, ³Kidney and Pancreas transplantation, KFSH&RC, Riyadh, Saudi Arabia, ⁴kFSH&RC, Riyadh, Saudi Arabia, ⁵Clinical Director, Histocompatibility and Immunogenetics Laboratory, KFSH&RC, Riyadh, Saudi Arabia, ⁶KFSH&RC, Riyadh, Saudi Arabia, ⁷Riyadh Elm University, Riyadh, Saudi Arabia, ⁸Clinical Transplant Coordinator, KFSH&RC, Riyadh, Saudi Arabia
*Purpose: We aim to examine the efficacy of Rituximab (RTX) monotherapy in reducing DSA in Highly Sensitised Living Donor Kidney Transplant (HS-LDKT) candidates and potentially…
2019 American Transplant Congress
Variable Outcomes of Recurrent Autoimmune Diabetes Post Pancreas Transplant Treated with Rituximab
K. Venkatachalam, A. Markwardt, B. Heady, T. Alhamad, A. Malone
Washington University, St. Louis, MO
*Purpose: Demonstrate the outcomes of treatment with rituximab in patients with autoimmune diabetes after pancreas transplant.*Methods: We present the treatment response to rituximab in 3…
2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
J. Lee,¹ J. Park,² Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,³ J. Lee,⁴ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…